
Creso Pharma
Overview
📋 About: Creso Pharma (ASX: CPH) is Medical cannabis and psychedelics company, developing therapeutic, nutraceutical and lifestyle products for human and animal health.
🌏 Macro Theme: World regulations are expected to open up as cannabis and psychedlics become an accepted form of alternative medicine.
Creso Pharma Company Milestones
✅ $9M Cap Raise @ 2.9c
✅ Convertible Notes Extinguished
✅ Key Appointment: Bruce Linton
✅ Next Investors Watchlist
✅ Improved Global Regulatory Environment for Cannabis
🌏 TGA Reclassifies Cannabis as a Schedule 4 drug
🌏 MORE Act Passed in the US
✅ $18M Cap Raise @19c per share
⚔️ MindMed NASDAQ Listing,(2)
✅ OTC Listing
🔲 Improved Global Regulatory Environment for Psychedelics
✅ [Unexpected News 1] Merger Announced with Red Light Holland
ℹ️ Red Light Holland Merger Terminated
🔲 [NEW] NASDAQ Listing
✅ [NEW] Key Management Appointment
🔲 [NEW] New (US) CEO Appointed
✅ [Unexpected News 2] Record Quarterly Revenue
🔲 Unexpected Positive Announcement 3
🔲 Next Investors Portfolio Launch?
Cannabis Products
Purchase orders listed here are over $150k only
✅ Purchase Order 1 $295K (Nutraceutical / Pharma Products)
✅ Purchase Order(s) 2 $415K + (Nutraceutical / Pharma Products)
✅ Purchase Order 3 $300K + (Nutraceutical / Pharma Products)
✅ Purchase Order 4 $247K + (Nutraceutical / Pharma Products)
✅ Purchase Order 5 $337K (Nutraceutical / Pharma Products)
🔲 Purchase Order 6 (Nutraceutical / Pharma Products)
🔲 Purchase Order 7 (Nutraceutical / Pharma Products)
🔲 Purchase Order 8 (Nutraceutical / Pharma Products)
✅ Purchase Order 1 $242K+ (Mernova Cannabis)
✅ Purchase Order(s) 2 $502K+ (Mernova Cannabis)
✅ Purchase Order 3 $177K+ (Mernova Cannabis)
✅ Purchase Order 4 $240K+ (Mernova Cannabis)
🔲 Purchase Order 5 (Mernova Cannabis)
🔲 Purchase Order 6 (Mernova Cannabis)
🔲 Purchase Order 7 (Mernova Cannabis)
🔲 Purchase Order 8 (Mernova Cannabis)
Psychedelics
✅ Plan to acquire Halucenex (psychedlics company) announced
✅ Increase Psilocybin Supply for Clinical Trials
✅ Halucenex receives Dealers License
✅ Complete Halucenex Acquisition
🔲 Phase II Clinical Trials recruitment
🔲 Phase II Clinical Trials begin
🔲 Phase II Clinical Trials - interim results
🔲 Phase II Clinical Trial Completed
🔲 Phase II Clinical Trial Results
🔲 Commercialisation milestone
Investment Plan
ASX:CPH is a medium term investment we hold and write about that is not currently in the portfolio. We took a position at 3c in October 2020 as a short term hold which upgraded to a medium hold after the company delivered. On March 26 2021 we increased our position at 19c. We are considering adding CPH to our long term portfolio if it can deliver a few more key milestones.
✅ Initial Investment @ 3c
✅ Increased Investment 19c
🔲 Increased Investment
✅ Price Increase 500% from Initial Entry
✅ Price Increase 1,000% from Initial Entry
🔲 Price Increase 2,000% from Initial Entry
🔲 12 Month Capital Gains Discount
✅ Free Carry
✅ Take Profits
🔲 Hold Remaining Position for Two Years
”Expected Company Milestones” are based on the company's publicly available execution plan and some assumptions made by our team on potential announcements that should de-risk the investment. “Our investment milestones” show our current long-term investment plan. Early stage investments are risky and there is no guarantee that the expected events will occur. The lists are not in sequential order.
Key
🔲 Expected Milestone
✅ Achieved Milestone
🟩 Above Average Result
🟨 Average (Expected) Result
🟧 Below Average Result
🟥 Negative Result
🌎 Macro Event
⚔️ Results from Other Company / Project
🔄 In Progress
[UPA] Unexpected Positive Announcement
[NEW] New Milestone Added
Our Past Commentary on Creso Pharma
Type | Date | Title |
---|---|---|
Article | 07-Dec-2020 | The USA Takes a Big Step to Decriminalise Cannabis: CPH Well Placed to Benefit |
Most recent catalysts for Creso Pharma

Jonathan Jackson 07/12/2020
The USA Takes a Big Step to Decriminalise Cannabis: CPH Well Placed to Benefit
Creso Pharma Limited (ASX: CPH) has substantial operations in North America and the US decision to legalise cannabis paves the way for the company to enter into the world’s largest recreational and medical cannabis market.

Catalyst Hunter 06/08/2017
CPH to Launch Innovative Hemp-based Animal Health Products with Virbac in Switzerland
CPH is a leading player in medicinal cannabis and cannabidiol (CBD) innovation, and develops cannabis and hemp-derived therapeutic-grade CBD nutraceuticals and medicinal cannabis products with wide patient and consumer reach for both human and animal health.